Natera, Inc. (NASDAQ:NTRA) is one of the high growth stocks outside tech analysts are bullish on. Evercore ISI Group has initiated coverage on Natera Inc. with an “Outperform” rating and a $170 price target, signaling optimism about the company’s strategic positioning in the growing genetic testing space. With Natera trading at $135.81 as of Monday’s close, the target implies a potential upside of roughly 25.2%.
This initiation reflects Evercore’s confidence in Natera’s ability to capture meaningful market share through its differentiated platform, particularly in high-growth areas like minimal residual disease (MRD) testing in oncology and non-invasive prenatal testing (NIPT). The firm’s pricing also suggests it sees earnings momentum or adoption trends that may not yet be fully reflected in the current valuation.
Unlike a broad sector endorsement, this coverage initiation appears to be a conviction call based on company-specific catalysts. These could include upcoming clinical data, reimbursement tailwinds, or commercial traction in new markets. While risks remain, such as competition and regulatory shifts, the bullish stance hints that Evercore believes the risk-reward profile is favorable.
If Natera delivers on key execution fronts over the coming quarters, the target may prove conservative, particularly if revenue re-acceleration or gross margin expansion materializes. Natera develops and markets genetic testing solutions for oncology, women’s health, and organ health applications.
READ NEXT: 10 Most Profitable Consumer Stocks to Buy Now and 10 Best High-Margin Pharma Stocks to Buy Now.
